What is Hexarelin?

Hexarelin is a synthetic growth hormone secretagogue peptide in the GHRP family. It activates the ghrelin receptor pathway and can stimulate growth-hormone release in human endocrine studies. [1][2][3]

Its profile is usually discussed as more potent and less selective than ipamorelin-style options because GH response, appetite, cortisol, prolactin, and cardiovascular research all appear in the literature. [1][2][3]

The name examorelin is sometimes used in scientific literature. Fitness-market hexarelin products are not FDA-approved medications and are not interchangeable with prescription growth-hormone therapy. [1][2][3]

What Hexarelin is investigated for

Hexarelin evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Potent GH-axis stimulation

Injectable

54% Emerging

GH-axis stimulation has the clearest human-facing support; muscle and recovery benefits need separate, lower-confidence interpretation. [1][6][4]

Human evidence

Human growth-hormone-secretagogue literature supports endocrine stimulation, but direct muscle-growth or recovery outcome trials for hexarelin are limited. [1][6][4]

Animal / mechanistic evidence

Mechanistic studies show growth-hormone secretagogue receptor binding and HPA-axis activity that explain the endocrine rationale. [1][6][4]

Cardiac tissue protection

Injectable

30% Limited

Cardiac protection is a plausible preclinical signal, not a proven cardiology use. [2][5][7]

Human evidence

Human cardiac-outcome evidence for hexarelin is not established in the cited literature. [2][5][7]

Animal / mechanistic evidence

Rat and isolated-heart models report protection against ischemia-reperfusion injury and post-infarction cardiac dysfunction. [2][5][7]

Lipid metabolism and insulin sensitivity

Injectable

28% Limited

Metabolic claims should be framed as mouse-model evidence, not human metabolic therapy. [3][1]

Human evidence

Human lipid or insulin-sensitivity outcomes for hexarelin are not established in the reviewed sources. [3][1]

Animal / mechanistic evidence

A nonobese insulin-resistant mouse model reported improved lipid metabolic abnormalities after hexarelin exposure. [3][1]

Muscle growth and recovery

Injectable

26% Limited

Muscle growth and recovery should remain a distinct preclinical GH-secretagogue claim. [1][14]

Human evidence

Human muscle-growth, fat-loss, lean-mass, or training-recovery outcome trials for hexarelin are not established in the cited literature. [1]

Animal / mechanistic evidence

GH-secretagogue reviews and a cachexia-model source support downstream muscle-recovery rationale, but not validated human performance effects. [1][8]

Neuroprotection against oxidative stress

Injectable

24% Limited

Neuroprotection is a preclinical oxidative-stress signal, not a human cognitive or neurological treatment claim. [15]

Human evidence

Human neuroprotection outcomes for hexarelin are not established. [15]

Animal / mechanistic evidence

Neuro-2A cell work links hexarelin with reduced hydrogen-peroxide-induced apoptotic toxicity through MAPK and PI3K/Akt pathway modulation. [15]

Lung inflammation and fibrosis

Injectable

22% Limited

Lung inflammation and fibrosis remain animal-model findings, not an established respiratory therapy. [16]

Human evidence

Human lung-injury or ARDS treatment outcomes for hexarelin are not established. [16]

Animal / mechanistic evidence

A murine acute-lung-injury model reported effects on lung mechanics, early inflammatory response, and fibrosis-related outcomes. [16]

Retinal ganglion cell neuroprotection

Injectable

20% Limited

Retinal neuroprotection is a narrow preclinical eye-injury signal and should not be generalized to human eye disease treatment. [17]

Human evidence

Human optic-nerve injury, glaucoma, or retinal-neuroprotection outcomes for hexarelin are not established. [17]

Animal / mechanistic evidence

A 2026 animal study investigated retinal ganglion cell survival after optic nerve injury. [17]

Evidence snapshot

Overall confidence

Emerging

54%

Human endocrine studies support acute GH release, so the page has a limited-human evidence base. Longer-term recovery, muscle, and cardiac benefits remain much less certain. [1][2][3][4]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

54%

Human evidence

Emerging

Direct human support is mainly endocrine-response data rather than durable outcome trials. That supports GH-axis activity, not established body-composition or recovery benefit. [1][2][3][4]

34%

Animal / preclinical

Limited

Animal and cell work supports ghrelin-receptor, GH-axis, and cardiac-protection plausibility. Direct human cardiac outcomes are still missing. [1][2][3][4]

54%

Mechanism support

Emerging

Hexarelin acts through the growth hormone secretagogue receptor, producing a GH-pulse signal. Some cardiac and metabolic mechanisms may be GH-independent, but those remain mostly preclinical. [1][2][3][4]

Forms & administration

Hexarelin is tracked as an injectable GH secretagogue. Short GH-pulse-style protocols are separate from approved growth-hormone medicines and from other GHRP products. [12][1][2]

Injectable

Dosing & protocols

The notes below separate published trial design from commonly discussed cosmetic or compounded-use patterns. They are educational context only, not a prescription or product instruction.

Typical Range

Common injectable protocols usually use 100-200 mcg per dose. [12][1][2]

Frequency

Common injectable schedules use 1-2 doses daily or intermittent blocks. [12][1][2]

Timing Considerations

Morning or before-bed timing is the common anchor when GH-pulse alignment is the goal. [12][1][2]

Cycle Length

Common injectable blocks run 4-8 weeks before comparing sleep, appetite, water retention, glucose, and recovery notes. [12][1][2]

What to expect

Same day

Injectable GH-pulse exposure can feel like appetite, sleepiness, and fullness changes before visible body-composition changes appear. [1][2][3][4][12]

Weeks 4-8

Injectable recovery feel, sleep depth, body-weight water shifts, and training tolerance may settle into a clearer pattern. [1][2][3][4][12]

After stopping

GH-pulse-related fullness and recovery signals fade after injectable Hexarelin exposure ends while training, nutrition, and sleep drive durability. [1][2][3][4][12]

Safety profile

Hexarelin safety is endocrine and route-aware: appetite, water retention, glucose, cortisol, prolactin, and sport status are the practical watch points. [14]

Common side effects

Appetite change [14]
Water retention [14]
Sleepiness [14]

Cautions

Glucose control [14]
Cortisol / prolactin sensitivity [14]
Prohibited in sport [14]

What we don't know

Repeated-cycle endocrine safety, long-term glucose effects, and product purity are not well characterized outside controlled study settings. [14]

Who Hexarelin is not for

Route-specific avoid and medical-review notes:

Active malignancy
Active malignancy warrants medical review or avoidance for Hexarelin. [1][2][3][4]
Pregnancy or breastfeeding
Pregnancy or breastfeeding warrants medical review or avoidance for Hexarelin. [1][2][3][4]
Uncontrolled diabetes or severe endocrine disease
Uncontrolled diabetes or severe endocrine disease warrants medical review or avoidance for Hexarelin. [1][2][3][4]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Insulin / glucose-lowering drugs
Insulin, sulfonylureas, or other glucose-lowering drugs can make GH-secretagogue glucose shifts harder to manage; this is a GH/insulin-axis caution. [14]
GH secretagogues
Somatropin, GHRPs, ipamorelin, or sermorelin can add to GH-axis stimulation, water retention, and appetite effects; this is a theoretical pathway caution. [14]
Prolactin-active drugs
Dopamine antagonists, dopamine agonists, or other prolactin-active drugs can make prolactin symptoms harder to interpret; this is a theoretical endocrine pathway caution. [14]

Regulatory status

United States

In the U.S. as of 2026-06-21, Hexarelin has no FDA-approved drug product for the reviewed injectable route. Research-market supply and compounded preparations are separate from approval; the 503A row names the current compounding bucket. [12][13][19][20]

Route	FDA drug approval	503A compounding
Injectable	Not Approved Hexarelin is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [12][13][19][20]	Not Listed Hexarelin is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval. [12][13][19][20]

Injectable

FDA drug approval

Not Approved

Hexarelin is not FDA-approved as an injectable drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [12][13][19][20]

503A compounding

Not Listed

Hexarelin is not in the current reviewed 503A compounding bucket for the injectable route; compounding status is separate from FDA drug approval. [12][13][19][20]

International

EU/Europe, UK, Canada, and Australia require product-specific checks in EMA/MHRA, Health Canada, and TGA registers. Research-market, supplement, or compounded availability should not be treated as therapeutic approval in those markets. [22][23][24][25]

Sports & competition

WADA S2 applies to GH secretagogues and GHRP-like agents; tested athletes should treat injectable hexarelin as prohibited unless a valid TUE or anti-doping review applies. [14][12][13][19][20]

How it works

Hexarelin is a growth hormone secretagogue that acts mainly through the GHSR-1a ghrelin receptor family. In practical terms, the first expected signal is a GH pulse with downstream IGF-1, appetite, glucose, prolactin, and cortisol implications rather than direct tissue repair. [1][2][3][4]

Injectable exposure and pulse timing shape interpretation. Peripheral binding-site and animal cardiac or metabolic findings keep hexarelin scientifically interesting, but those signals do not make it a general cardioprotective or body-composition therapy in people without route-matched clinical outcomes. Those outcomes still need controlled human endpoints, not just transient hormone movement. [1][2][3][4]

Research gaps & open questions

What the current literature has not yet settled about Hexarelin:

A key evidence gap is longer controlled human outcome trials. [1][2][3][4]

A key evidence gap is dose-response and endocrine-marker safety over repeated cycles. [1][2][3][4]

A key evidence gap is human cardiovascular endpoint studies. [1][2][3][4]

Common questions

Is hexarelin FDA-approved?

No. Hexarelin is not FDA-approved in the U.S. for injectable drug use, and compounded or research-market products are not FDA-approved. [12][13][1][2][19]

How is hexarelin different from ipamorelin?

Hexarelin is a GHRP-style ghrelin-receptor agonist often framed as less selective; ipamorelin is usually positioned around cleaner GH-secretagogue pharmacology. [12][13][1][2]

Does hexarelin protect the heart?

Not proven. Preclinical cardiac studies exist, but injectable hexarelin has no established human cardioprotective protocol or outcome standard. [12][13][1][2]

Myths & misconceptions

Myth

A GH pulse proves better recovery.

Reality

GH biomarkers are indirect; recovery outcomes need direct human data. [1][2][3][4]

Myth

Cardiac research makes hexarelin a heart treatment.

Reality

The cardiac literature is mainly experimental and does not support treatment claims. [1][2][3][4]

History & discovery

Hexarelin belongs to the growth-hormone-secretagogue era, when short synthetic peptides were used to explore GH release outside classic GHRH signaling. Its history starts in endocrine pharmacology, not sports recovery. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2][3][4]

Growth-hormone secretagogue work placed hexarelin in the ghrelin-receptor/GHRP family, where GH pulses, appetite signaling, ACTH, cortisol, and prolactin became part of the interpretation. [1][2][3][4]

Later animal and tissue studies explored cardiac protection and lipid-metabolism signals. Those findings broadened the research story while keeping human wellness, recovery, and cardioprotection claims separate. [1][2][3][4]

Published research 17 studies

[1]

The Safety and Efficacy of Growth Hormone Secretagogues.

Sex Med Rev, 2018 Jan. review.

[2]

The Growth Hormone Secretagogue Hexarelin Protects Rat Cardiomyocytes From in vivo Ischemia/Reperfusion Injury Through Interleukin-1 Signaling Pathway.

Int Heart J, 2017 Apr 6. animal.

[3]

Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice.

Endocrinology, 2017 Oct 1. animal.

[4]

Growth hormone secretagogue binding sites in peripheral human tissues.

J Clin Endocrinol Metab, 2000 Oct. review.

[5]

Hexarelin, a growth hormone secretagogue, protects the isolated rat heart from ventricular dysfunction produced by exposure to calcium-free medium.

Pharmacol Res, 2000 Aug. animal.

[6]

The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin.

J Clin Endocrinol Metab, 1999 Jul. human clinical.

[7]

The growth hormone secretagogue hexarelin improves cardiac function in rats after experimental myocardial infarction.

Endocrinology, 2000 Jan. animal.

[8]

JMV2894, a novel growth hormone secretagogue, accelerates body mass recovery in an experimental model of cachexia.

Endocrine, 2017 Oct. animal.

[9]

Cortistatin, but not somatostatin, binds to growth hormone secretagogue (GHS) receptors of human pituitary gland.

J Endocrinol Invest, 2001 Jan. review.

[10]

Absence of binding of targeted analogs of somatostatin carrying cytotoxic radicals or radionuclides to growth hormone secretagogue receptors on human myocardium.

Life Sci, 2003 Apr 25. review.

[11]

Pharmacological profile of a new orally active growth hormone secretagogue, SM-130686.

J Endocrinol, 2001 Dec. review.

[12]

Drugs@FDA/openFDA query for Hexarelin

U.S. Food and Drug Administration. database query.

[13]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[14]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.

[15]

Hexarelin Modulation of MAPK and PI3K/Akt Pathways in Neuro-2A Cells Inhibits Hydrogen Peroxide-Induced Apoptotic Toxicity.

PubMed, 2021. in vitro.

[16]

Hexarelin modulates lung mechanics, inflammation, and fibrosis in acute lung injury.

PubMed, 2021. animal.

[17]

Hexarelin promotes the survival of retinal ganglion cells after optic nerve injury.

PubMed, 2026. animal.